Aquestive Therapeutics, Inc. (AQST): Nasdaq/NYSE listing notice — Aquestive receives Nasdaq deficiency notice for bid price below $1.00

Aquestive Therapeutics, Inc.

Nasdaq notified Aquestive on Dec 30, 2022 that its common stock bid price was below $1.00 for 30 consecutive days.
Company has 180 days, until June 28, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by deadline, Aquestive may transfer to Nasdaq Capital Market for an additional 180-day cure period.
Company may consider a reverse stock split to address the bid price deficiency.
Failure to regain compliance could result in delisting of AQST common stock.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aquestive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

December 30, 2022, Aquestive Therapeutics, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has 180 calendar days, or until June 28, 2023, to regain compliance with the Minimum Bid

View on SEC.gov

Browse all listing & compliance notices →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.